Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377099 | 0.88 | FFAR1 (0.56) | FFAR1FFAR4AKR1B1HDAC1HDAC7 | |
| SCHEMBL5381126 | 0.88 | PTGDR2 (0.48) | FFAR1FFAR4HDAC1HDAC7PPARD | |
| SCHEMBL16381990 | 0.85 | HRH3 (0.40) | FFAR1FFAR4HDAC1HDAC7 | |
| SCHEMBL5381994 | 0.84 | KMT2A (0.44) | FFAR1FFAR4HDAC1HDAC7 | |
| SCHEMBL5385908 | 0.84 | FFAR1 (0.49) | FFAR1FFAR4AKR1B1HDAC1HDAC7 | |
| SCHEMBL5373709 | 0.83 | FFAR1 (0.61) | FFAR1AKR1B1 | |
| SCHEMBL7549149 | 0.82 | GPR34 (0.43) | HDAC1HDAC7 | |
| SCHEMBL5387558 | 0.80 | ALDH1A1 (0.51) | FFAR1FFAR4AKR1B1HDAC1HDAC7 | |
| SCHEMBL5380307 | 0.80 | FFAR1 (0.64) | FFAR1PPARD | |
| SCHEMBL5380946 | 0.80 | CYP19A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731505-B1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-14 | — | — | EP | disclosed |
| EP-2253315-A1 | Alkoxyphenylpropanoic acid derivatives | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253315-A1 | Alkoxyphenylpropanoic acid derivatives | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1731505-A1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | GPR119, FFAR1, GPR55 | FFAR1 2/4885FFAR4 6/4885AKR1B1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.